Racial Disparities in Systemic Sclerosis: Short‐ and Long‐Term Outcomes Among African American Participants of SLS I and II
Open Access
- 5 December 2020
- journal article
- research article
- Published by Wiley in ACR Open Rheumatology
- Vol. 3 (1) , 8-16
Abstract
Objective: To evaluate short‐ and long‐term outcomes of African American (AA) participants of Scleroderma Lung Studies (SLS) I and II.Methods: SLS I randomized 158 participants with systemic sclerosis‐interstitial lung disease (SSc‐ILD) to 1 year of oral cyclophosphamide (CYC) versus placebo. SLS II randomized 142 participants with SSc‐ILD to 1 year of oral CYC followed by 1 year of placebo versus 2 years of mycophenolate (MMF). Joint models compared the course of forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) between AA and non‐AA, and Cox proportional hazard models assessed long‐term morbidity and mortality outcomes.Results: In SLS I, there was no difference in the course of the FVC or DLCO between AA and non‐AA in either treatment arm. In SLS II, AA had an improved course of the FVC compared with non‐AA in the CYC arm; in the MMF arm, there was no difference in FVC course. There was no difference in DLCO course in either arm. Time to death and respiratory failure were similar for AA and non‐AA in SLS I. There was a trend for improved survival and time to respiratory failure in AA compared with non‐AA in SLS II. AA race was not independently associated with mortality in the SLS I or II in the Cox models.Conclusion: Data from two randomized controlled trials demonstrated that AA patients with SSc‐ILD have similar morbidity and mortality outcomes compared with non‐AA patients. These findings contrast with the racial disparities described in prior observational studies and warrant further investigation.Keywords
Funding Information
- Scleroderma Foundation (Early Investigator Award)
- Rheumatology Research Foundation (Scientist Development Award)
- National Heart, Lung, and Blood Institute (R01 HL089758, R01 HL089901)
This publication has 21 references indexed in Scilit:
- Reporting of Limitations of Observational ResearchJAMA Internal Medicine, 2015
- A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosisArthritis & Rheumatism, 2012
- Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trialsRheumatology, 2010
- Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than PlaceboChest, 2009
- Cyclophosphamide versus Placebo in Scleroderma Lung DiseaseNew England Journal of Medicine, 2006
- Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US populationArthritis & Rheumatism, 2003
- Spirometric Reference Values from a Sample of the General U.S. PopulationAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Racial differences in scleroderma among women in MichiganArthritis & Rheumatism, 1997
- Incidence OF systemic sclerosis in allegheny county, Pennsylvania. A twenty‐year study of hospital‐diagnosed cases, 1963–1982Arthritis & Rheumatism, 1997
- Race/Ethnicity and Socioeconomic Status: Measurement and Methodological IssuesInternational Journal of Health Services, 1996